Caffeine, codeine, meprobamate, paracetamol (Stilpane, Painrite Forte, Megapyn, Ban Pain, Noralget, Antipyn Forte)

Caffeine, codeine, meprobamate, paracetamol

Pharmacare limited û woodmead

S5Read from the PI-PIL document and verified

Registration

Applicant: Pharmacare limited û woodmead
Certificate holder: Pharmacare limited
Registrations: 6
Schedule source: SAHPRA documentation

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Stilpane EACH TABLET CONTAINS CAFFEINE 32 mg CODEINE PHOSPHATE 8 mg MEPROBAMATE 150 mg PARACETAMOL 320 mg	150 mgTablets	M0002M/2.9/2Approved 21 October 2025	Registered	S5	PI PIL
Painrite forte EACH CAPSULE CONTAINS CAFFEINE 48 mg CODEINE PHOSPHATE 8 mg MEPROBAMATE 150 mg PARACETAMOL 320 mg	Not listed	Q0242Q/2.9/242	Cancelled	Not determined	None
Megapyn tablets EACH TABLET CONTAINS CAFFEINE ANHYDROUS 32 mg CODEINE PHOSPHATE 8 mg MEPROBAMATE 150 mg PARACETAMOL 320 mg	Tablets	X0240X/2.8/240	Cancelled	Not determined	None
Ban pain tablets EACH TABLET CONTAINS CAFFEINE 32,0 mg CODEINE PHOSPHATE 8,0 mg MEPROBAMATE 150,0 mg PARACETAMOL 320,0 mg	Tablets	Y0051Y/2.8/51	Cancelled	Not determined	None
Noralget tablets EACH TABLET CONTAINS CAFFEINE 32 mg CODEINE PHOSPHATE 8 mg MEPROBAMATE 150 mg PARACETAMOL 320 mg	Tablets	Y0118Y/2.8/118	Cancelled	Not determined	None
Antipyn forte EACH TABLET CONTAINS CAFFEINE ANHYDROUS 32 mg CODEINE PHOSPHATE 8 mg MEPROBAMATE 150 mg PARACETAMOL 320 mg	Not listed	Y0321Y/2.8/321	Registered	Not determined	None

Regulatory status

Where S5 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only, with tighter controls on repeats.

Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S5, read from the product's PI-PIL leaflet.

The Consolidated Schedules list this ingredient up to S6; the leaflet's S5 applies to this product.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.

Consolidated Schedules listings for Caffeine, codeine phosphate, meprobamate, paracetamol

S6: Codeine
- single component codeine preparations;
- oral solid preparations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3)
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export. (S2, S3)
Consolidated Schedules 06 July 2026, lines 10128 to 10136
S5: Meprobamate
Consolidated Schedules 06 July 2026, line 9539
S3: Caffeine
- when intended for injection.
Consolidated Schedules 06 July 2026, line 3256
S3: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 3350 to 3372
S3: Paracetamol
- when intended for injection.
Consolidated Schedules 06 July 2026, line 4093
S2: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit; (S3)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit; (S3)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 1758 to 1778
S2: Paracetamol
- when contained in rectal suppositories, or
- when contained in modified release formulations. (S0, S1, S3)
Consolidated Schedules 06 July 2026, lines 2496 to 2500
S1: Paracetamol
- immediate release tablets or capsules each containing 500 milligrams or less of paracetamol, or in individually wrapped powders or in sachets containing 1 000 milligrams or less of paracetamol, subject to - (i) a maximum of 12,5 grams of paracetamol per primary pack, and (ii) in the case of tablets or capsules, presented in blister strip packaging or in containers with child-resistant closures; and (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
- in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres or in paediatric drops containing 120 milligrams or less of paracetamol per 1,2 millilitres, subject to - (i) a maximum of 100 millilitres per primary pack in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres; (ii) a maximum of 20 millilitres per primary pack in the case of the paediatric drops; (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
- when contained in rectal suppositories. (S2)
- when contained in modified release formulations. (S2)
- when intended for injection. (S3)
Consolidated Schedules 06 July 2026, lines 958 to 997

Pharmacological class: Other analgesics. (class 2.9)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

This medication's schedule (S5) has been verified from official SAHPRA documents with 90% confidence.

Professional information (PI)For healthcare professionals Patient information leaflet (PIL)For patients and carers

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading Wikipedia summary

Research articles

Loading PubMed articles